【Bangalore】Infosys, India’s second largest software services company, expects the recent spate of mergers and acquisitions (M&As) in the global pharmaceutical sector to boost its life sciences business over the next 12 months.
“There is a lot of M&A activity happening in the life sciences space. When M&A is typically initiated, budgets are tightly controlled, because companies are hoarding cash to ward off (rival bids) and to make the sale happen,” said Manish Tandon, senior vice-president and global segment head of life sciences. “As these M&As are fructified in the next six months to a year, a lot of new work will be generated. We are confident we will get a lot of business there.”
○Venus Remedies gets patent for anti-ICU infection drug
【Chandigarh】The GLP-accredited research centre of Venus Remedies Limited, headquartered at Panchkula in Haryana, Venus Medicine Research Center has received another patent grant for a novel antibiotic product, VRP008, an anti-ICU infection drug.
This product, which consists of a carbapenem and a novel amino glycoside (NCE entity) from EPO, is the outcome of eight years of research by Venus Medicine Research Centre, pioneering into antimicrobial resistance research.
【News source】
Pharma M&As to drive Infosys' life sciences biz
Venus Remedies gets patent for anti-ICU infection drug
Free download of "The Origin of Christianity"
Special sale for Ad Space
Readers' Voice
Your Comments
SEAnewsFacebook
SEAnewsGoogle